Emerging drugs for focal epilepsy

Bibliography

• Ngugi AK, Kariuki SM, Bottomley C, Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011;77(10):1005-12
   PubMed Web of Science ®Google Scholar
• de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 2008;12(4):540-6
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Beghi E, Forsgren L, Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48(12):2224-33
   PubMed Web of Science ®Google Scholar
• Mula M. New antiepileptic drugs: molecular targets. Cent Nerv Syst Agents Med Chem 2009;9(2):79-86
   PubMedGoogle Scholar
• Kwan P, Arzimanoglou A, Berg AT, Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069-77
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010;51(1):7-26
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5(7):553-64
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4(1):18-61
   PubMed Web of Science ®Google Scholar
• Lee CY, Fu WM, Chen CC, Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 2008;49(5):888-97
   PubMed Web of Science ®Google Scholar
• Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):S10-16
   PubMed Web of Science ®Google Scholar
• Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr 2007;7(1):15-22
   PubMedGoogle Scholar
• Yu FH, Yarov-Yarovoy V, Gutman GA, Catterall WA. Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol Rev 2005;57(4):387-95
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res 2006;68(1):22-8
   PubMed Web of Science ®Google Scholar
• Jung HY, Mickus T, Spruston N. Prolonged sodium channel inactivation contributes to dendritic action potential attenuation in hippocampal pyramidal neurons. J Neurosci 1997;17(17):6639-46
   PubMed Web of Science ®Google Scholar
• Catterall WA, Striessnig J, Snutch TP, Perez-Reyes E. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. Pharmacol Rev 2003;55(4):579-81
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004;20(6):1566-76
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39(11):2139-46
   PubMed Web of Science ®Google Scholar
• Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci 2000;23(9):393-8
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Hirai H, Iino M, Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology 2009;56(2):499-506
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295(3):1086-93
   PubMed Web of Science ®Google Scholar
• Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res 2005;63(1):17-25
   PubMed Web of Science ®Google Scholar
• Madeja M, Margineanu DG, Gorji A, Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45(5):661-71
   PubMed Web of Science ®Google Scholar
• Deeks ED. Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. CNS Drugs 2011;25(10):887-900
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15(5):339-50
   PubMed Web of Science ®Google Scholar
• Barrese V, Miceli F, Soldovieri MV, Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin Pharmacol 2010;2:225-36
   PubMedGoogle Scholar
• Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005;6(3):215-29
   PubMed Web of Science ®Google Scholar
• Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol Sci 2003;24(10):542-9
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 2001;40(1):28-35
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11(2):56-63
   PubMed Web of Science ®Google Scholar
• Vezzani A. Inflammation and epilepsy. Epilepsy Curr 2005;5(1):1-6
   PubMedGoogle Scholar
• Vezzani A, Bartfai T, Bianchi M, Therapeutic potential of new antiinflammatory drugs. Epilepsia 2011;52(Suppl 8):67-9
   PubMedGoogle Scholar
• Ichiyama T, Okada K, Lipton JM, Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 2000;857(1-2):246-51
   PubMed Web of Science ®Google Scholar
• Matoth I, Pinto F, Sicsic C, Brenner T. Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. Neurosci Res 2000;38(2):209-12
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92(2-3):89-124
   PubMed Web of Science ®Google Scholar
• Laxer K, Blum D, Abou-Khalil BW, Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia 2000;41(9):1187-94
   PubMed Web of Science ®Google Scholar
• Monaghan EP, Navalta LA, Shum L, Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997;38(9):1026-31
   PubMed Web of Science ®Google Scholar
• Kerrigan JF, Shields WD, Nelson TY, Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res 2000;42(2-3):133-9
   PubMed Web of Science ®Google Scholar
• Pieribone VA, Tsai J, Soufflet C, Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 2007;48(10):1870-4
   PubMed Web of Science ®Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52(7):1331-40
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79(6):589-96
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78(18):1408-15
   PubMed Web of Science ®Google Scholar
• Rektor I, Krauss GL, Bar M, Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263-9
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2012; Epub ahead of print
   Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Howes JF, Bell C. Talampanel. Neurotherapeutics 2007;4(1):126-9
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73(1):1-52
   PubMed Web of Science ®Google Scholar
• Besag FM, Patsalos PN. New developments in the treatment of partial-onset epilepsy. Neuropsychiatr Dis Treat 2012;8:455-64
   PubMed Web of Science ®Google Scholar
• Auberson YP. BGG492, a competitive ampa/kainate antagonist for the treatment of epilepsy. 2émes Journeées Scientifiques du Médicament; Grenoble; 2012. p. 9
   Google Scholar
• Russo E, Gitto R, Citraro R, New AMPA antagonists in epilepsy. Expert Opin Investig Drugs 2012;21(9):1371-89
   PubMed Web of Science ®Google Scholar
• Pitkanen A, Mathiesen C, Ronn LC, Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 2007;74(1):45-54
   PubMed Web of Science ®Google Scholar
• Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 2009;50(Suppl 12):49-50
   PubMed Web of Science ®Google Scholar
• Gormsen L, Finnerup NB, Almqvist PM, Jensen TS. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg 2009;108(4):1311-19
   PubMed Web of Science ®Google Scholar
• Maroso M, Balosso S, Ravizza T, Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 2011;8(2):304-15
   PubMed Web of Science ®Google Scholar
• Ravizza T, Lucas SM, Balosso S, Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia 2006;47(7):1160-8
   PubMed Web of Science ®Google Scholar
• Ravizza T, Noe F, Zardoni D, Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiol Dis 2008;31(3):327-33
   PubMed Web of Science ®Google Scholar
• Cornelis S, Kersse K, Festjens N, Inflammatory caspases: targets for novel therapies. Curr Pharm Des 2007;13(4):367-85
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75(6):519-25
   PubMed Web of Science ®Google Scholar
• Pharmaprojects. Pharmaprojects - copyright to Citeline Drug Intelligence (an informa business). 2012
   Google Scholar
• Labiner DM. DP-VPA D-Pharm. Curr Opin Investig Drugs 2002;3(6):921-3
   PubMedGoogle Scholar
• Dahan A, Duvdevani R, Shapiro I, The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release 2008;126(1):1-9
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Weintraub D, Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68(20):1701-9
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 2009;23(2):121-37
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009;11(1):1-9
   PubMed Web of Science ®Google Scholar
• Mula M. Treatment-emergent psychiatric adverse events of antiepileptic drugs in epilepsy: how can we avoid them? Neuropsychiatry 2011;1(4):371-6
   Google Scholar
• Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem 2008;2:21-39
   PubMedGoogle Scholar